Evoke Pharma (NASDAQ:EVOK) Major Shareholder Sells $95,850.00 in Stock

Evoke Pharma, Inc. (NASDAQ:EVOK) major shareholder Roger Klein sold 9,000 shares of Evoke Pharma stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $10.65, for a total value of $95,850.00. Following the completion of the transaction, the insider directly owned 29,000 shares of the company’s stock, valued at approximately $308,850. This represents a 23.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Evoke Pharma Stock Performance

Shares of EVOK stock opened at $10.69 on Monday. The company has a market capitalization of $16.68 million, a price-to-earnings ratio of -4.18 and a beta of -0.14. Evoke Pharma, Inc. has a one year low of $1.94 and a one year high of $10.79. The company’s 50-day moving average is $5.39 and its 200 day moving average is $4.43.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Thursday, August 14th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.32). The firm had revenue of $3.75 million during the quarter, compared to the consensus estimate of $3.80 million. Evoke Pharma had a negative return on equity of 99.48% and a negative net margin of 42.07%.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. National Wealth Management Group LLC purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 80,130 shares of the specialty pharmaceutical company’s stock, valued at approximately $398,000. National Wealth Management Group LLC owned about 5.14% of Evoke Pharma at the end of the most recent reporting period.

Analysts Set New Price Targets

Several analysts have commented on the company. Wall Street Zen upgraded Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, September 7th. Laidlaw downgraded Evoke Pharma from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evoke Pharma in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.